Hepatitis B - Pipeline Review, H2 2016
"Hepatitis
B - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides an
overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis
B is a potentially life-threatening liver infection caused by the
hepatitis B virus. Hepatitis B virus can cause an acute illness with
symptoms that last several weeks, including yellowing of the skin and
eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and
abdominal pain. Risk factors include age, severe kidney disease,
hemophilia, share needles during drug use and born to a hepatitis-b
infected mother. Treatment includes antiviral drugs.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Hepatitis B - Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Hepatitis B
(Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
The
Hepatitis B (Infectious Disease) pipeline guide also reviews of key
players involved in therapeutic development for Hepatitis B and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II,
Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are
2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the
Universities portfolio in Phase II, Preclinical and Discovery stages
comprises 3, 7 and 6 molecules, respectively.Hepatitis B.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Hepatitis B (Infectious Disease).
-
The pipeline guide reviews pipeline therapeutics for Hepatitis B
(Infectious Disease) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Hepatitis B
(Infectious Disease) therapeutics and enlists all their major and
minor projects.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Hepatitis B (Infectious Disease).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Hepatitis B (Infectious Disease) pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Comments
Post a Comment